Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.4 pts more than Nifty Microcap 250 and 10.1 pts more than its Other Financial Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Biogen Pharmachem Industries (formerly Sun Techno Overseas) reported a sharp swing back to profit in Q1 FY26. Revenue from operations stood at Rs. 154.28 lakhs versus a negative Rs. 9.09 lakhs in the year-ago quarter. Net profit was Rs. 134.48 lakhs, compared with a net loss of Rs. 15.83 lakhs in Q1 FY25. Basic EPS for the quarter was Rs. 0.01. Paid-up equity share capital rose to Rs. 9,026.03 lakhs from Rs. 6,526.03 lakhs a year earlier, suggesting fresh equity infusion during the year. The statutory auditor (Rishi Sekhri and Associates) issued a clean limited review report with no qualifications.
Numbers show a dramatic turnaround from loss to profit, but the FY25 balance sheet carried negative other equity of Rs. 903.26 lakhs, signalling accumulated losses that investors should weigh. With very low revenue base and EPS, this is a micro-cap story where big percentage swings can occur on small absolute changes.